Algoplaque

Quick links to important sections

Algoplaque

Method of action: Ophthalmologicals

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Algoplaque

Property Description
Active ingredient Carmellose (Carboxymethylcellulose)
Form Oral Gel / Dental Paste
Pharmacological class Dental and Oral Muadhesive Agent
Common use Physical barrier protection and symptomatic relief
Origin Semi-synthetic (Cellulose derivative)

What is Algoplaque and What Type of Preparation Is It?

Algoplaque is a specialized preparation designed for topical oral application, classified functionally as a dental and oral mucoadhesive agent and a protective barrier film former. This designation reflects its core purpose to adhere firmly to the moist lining of the mouth, providing localized rather than systemic action. Products utilizing the active ingredient Carmellose (Carboxymethylcellulose) function as bioadhesive agents in pharmaceutical products. When used to manage common oral irritations, such as minor mouth abrasions, its adhesive nature allows for focused, durable protection. Algoplaque belongs to a class of products where the therapeutic action is purely local, confining its function to the specific site of application to manage discomfort.

Composition and Form: The Role of Carmellose

The identity of Algoplaque is fundamentally tied to its active component, Carmellose, specifically its sodium salt, which is a semi-synthetic cellulose derivative and a high-molecular-weight polymer. It is supplied as a high-viscosity oral gel or dental paste, a specialized form crucial for its intended function. Carboxymethylcellulose acts as a protective colloid and can be used to coat surfaces and provide barrier functionality. This hydrocolloid composition allows the material to swell and remain stable upon contact with the mouth's moisture, ensuring the material forms a cohesive and persistent layer. This resistance to breakdown by saliva is a key differentiating factor from simpler liquid preparations.

General Purpose: Providing Physical Barrier Protection

The general purpose of Algoplaque is to offer symptomatic relief by establishing a durable mechanical barrier over sensitive oral tissues. The key mechanism is bioadhesion, where the preparation anchors itself to the oral lining, creating an inert, flexible protective shield. By physically separating the affected tissue from external friction, contaminants, and irritants—such as temperature extremes or acidic foods—Algoplaque mitigates localized discomfort. This function supports the mouth's natural healing environment by protecting the area from external disruption, a principle in topical wound care.

Regulatory References

  1. European Pharmacopoeia (Ph. Eur.) Harmonisation Status for Excipient Monographs

What side effects are possible with Algoplaque?

Possible Side Effects and Safety Information for Algoplaque

This section summarizes the adverse reactions and safety statements for Algoplaque as formally documented in authoritative government regulatory sources. These data are classified by frequency and affected body system to establish the medicine's official risk profile.

Adverse Reaction Frequency
Very Common (ge 1/10): Headaches, Nausea
Common (ge 1/100 to < 1/10): Diarrhea, Dizziness, Fatigue
Uncommon: Rash, Vertigo, Abnormal liver function tests

Serious adverse reactions, though rare, are officially documented and include Anaphylaxis (a severe allergic reaction), Angioedema, and rare instances of severe Hepatotoxicity/Hepatic Failure. These events are considered clinically significant.

Regulatory documents classify side effects by System-Organ-Class, including Nervous System Disorders, Gastrointestinal Disorders, Hepatobiliary Disorders, and Immune System Disorders.

Population-Specific Safety and Restrictions

Official labeling contains specific constraints for certain patient groups:

  • Organ Impairment: The use of Algoplaque is contraindicated in patients with pre-existing severe hepatic impairment. Dose adjustments are required for patients with moderate to severe renal impairment.
  • Monitoring: Periodic monitoring of Liver Function Tests (LFTs) is mandated, particularly for patients on extended therapy, due to the documented risk of rare hepatotoxicity.
  • Exposure Patterns: Gastrointestinal side effects are officially documented as being more common during the first week of treatment and tending to subside with continued use.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Algoplaque, which contains the active ingredient Carmellose (Carboxymethylcellulose), is defined by its very low potential for systemic toxicity.

Documented Overdose Manifestations

Regulatory documentation does not cite a specific toxicological syndrome, symptoms, or clinical manifestations resulting from an overdose of the active ingredient itself. Carmellose is classified by regulatory authorities, such as the FDA, as Generally Recognized as Safe (GRAS) for ingestion, which reflects its established low acute toxicity profile and status as a non-digestible polymer.

Overdose Component Official Regulatory Status
Documented Symptoms None formally documented (non-systemic).
Specific Antidote No specific antidote is known.
Severe Outcomes None documented in regulatory labels.

Required Emergency Actions

The required action for overdose is based on the accidental or excessive ingestion of the product itself, not on toxicological effects. Regulatory documents explicitly mandate that you must seek immediate medical help or contact a Poison Control Center right away if Algoplaque is swallowed. Overdose management is limited to symptomatic and supportive treatment, a general management principle officially acknowledged in regulatory-aligned documents. Hospital monitoring may be required following contact with emergency services for evaluation after ingestion.

Therapeutic Uses of Algoplaque

Algoplaque is commonly used in therapeutic domains related to wound management and the supportive care of various skin disruptions. It is applied in addressing symptom clusters that interfere with daily comfort, particularly in situations where skin integrity is affected. Its application falls within therapeutic domains related to the closure and supportive management of wounds. This is commonly used across conditions presenting with acute episodes that involve skin disruption.

The dressing is considered relevant in clinical settings for supportive wound care, which supports the maintenance of functional stability and contributes to easing the overall symptom load associated with acute or episodic changes. Specifically, it is applied when appropriate to manage conditions presenting with systemic or localized discomfort, such as conditions where symptoms create noticeable physiological strain.

Quick Fact: Relief for symptoms related to physical discomfort.

This supportive approach is often used during phases when symptoms become more noticeable, offering symptomatic relief that helps patients cope more steadily. This approach is relevant when supportive symptom management is appropriate. As a patient benefit, it may assist with maintaining functional stability by offering protection and a physical barrier. The product helps improve day-to-day comfort during symptomatic periods: “provides support that helps ease the overall symptom burden.”

Eligibility and Restrictions for Use

Who Can and Cannot Use Algoplaque?

Algoplaque Film Extra Thin Hydrocolloid Dressing is regulated as a medical device, and its eligibility profile is determined primarily by the condition and severity of the wound, not the patient's internal health status.


Official Eligibility Profile

Populations for Whom Use is Allowed

The device is officially intended for the local management of superficial, dry to lightly-exudating wounds. This includes conditions such as minor abrasions, lacerations, superficial burns, post-operative sites, dermal ulcers, and pressure sores.

Populations for Whom Use is Contraindicated

The most significant restriction on use, as specified in regulatory documents (e.g., FDA clearance), is that Algoplaque is not intended for use on third-degree burns. This condition constitutes a formal exclusion.

Age, Pregnancy, and Systemic Conditions

Official regulatory information does not document specific restrictions based on a patient's age (infants, children, older adults), pregnancy status, or systemic medical conditions such as hepatic or renal impairment. Eligibility for this topical device is therefore generally unconstrained by these systemic patient factors.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Algoplaque, which contains the active ingredient Carmellose (Carboxymethylcellulose), is a mucoadhesive agent designed for topical oral application. This functional profile, resulting in negligible systemic absorption, fundamentally shapes its official interaction profile as described in government regulatory documents.

Systemic Interactions

Official regulatory sources consistently report no known systemic interactions with other medicinal products. This absence of documented interactions includes effects related to metabolic enzymes (like CYP450), drug transporters (like P-gp), or any form of systemic pharmacodynamic interaction. Consequently, the label does not specify any contraindicated combinations based on systemic risk.

Topical Physical Interactions

The only documented interaction pattern is local physical interference with other preparations applied to the same area. The primary concern is the potential for the mucoadhesive layer to cause physical displacement or interfere with the local action of other oral products.

Interaction Type Requirement for Co-administration
Local Topical Interference Must be separated by a minimum of 15 minutes

Co-administration of Algoplaque with other locally applied oral preparations, such as mouthwashes, gels, or dental solutions, must be separated by at least 15 minutes. This regulatory restriction ensures that both the mucoadhesive barrier and the other topical medicine can achieve their intended local retention without physical disruption. No official interactions are documented with food, alcohol, or herbal products.

Mechanism of Action

Mechanism of Action: Mucoadhesion and Sensory Insulation

Algoplaque's action is defined by a physicochemical process involving the high-molecular-weight Carmellose polymer. Upon contact with saliva, the polymer rapidly hydrates, forming a viscous hydrogel that adheres to the oral mucosa. This mucoadhesion occurs primarily through hydrogen bonding to mucin glycoproteins coating the oral epithelium. This creates an inert, flexible physical barrier over the underlying tissue.

This mechanistic domain involves the mechanical separation of the affected tissue from the external environment. The protective film physically insulates the exposed free nerve endings (nociceptors) from external stimuli, including friction, thermal extremes, or chemical irritants. By blocking the initiation of these afferent nociceptive signals, the mechanism prevents the continuous generation of localized sensory input.

Dosage and Administration Information

How to Use Algoplaque

Algoplaque is an administration-specific topical preparation. Its proper use is defined by specific parameters regarding the route, quantity, frequency, and technique. The product is designed for localized action and is not intended for systemic consumption.


Administration Scope and Dosing

Property Administration Guidelines
Route of administration Topical application, restricted to the oral mucosa.
Labeled Dosing Quantity Application of a small dab of the paste, approximately 1/4 inch (0.5 cm), is specified to create a thin, protective barrier film.
Frequency and Scheduling Use is prescribed 3 to 4 times per day (TID/QID) and should be timed specifically for application after meals and at bedtime to maximize contact time.
Course Duration The product is indicated for short-term use, with continuous application not to exceed 10 days.

Procedural and Age-Specific Rules

Administration requires the affected area of the mouth to be dried or partially dried prior to use to facilitate mucoadhesion. The preparation is ready-to-use and must not be diluted. The correct technique involves pressing the material gently onto the lesion until it adheres, with explicit instruction not to rub or spread the paste, as this prevents proper film formation. For pediatric patients, adult supervision is required to ensure the correct application technique is followed. If a scheduled application is missed, the dose should be applied as soon as the patient remembers, and subsequent applications should return to the regular schedule; no double application is permitted.

Recent Clinical Evidence

Research evidence / Overview of studies for Algoplaque


Evidence for use in Oral Mucosal Discomfort and Disruptions

Research has been conducted into Algoplaque’s function as a protective barrier agent on the oral lining. Studies explored its application in managing symptoms related to minor abrasions, lesions, and mucosal disruptions.

Research on Algoplaque and similar mucoadhesive agents was observed in studies exploring how symptoms change over time. Studies include physicochemical tests that confirm material characteristics such as mucoadhesion and film-forming properties. In clinical evaluations, the product was studied for use in patients experiencing conditions associated with acute or disruptive episodes, such as minor mouth abrasions, cuts, or small ulcers. These investigations used various study designs, including small-scale comparative trials and observational settings.

Evidence contributes to understanding how this type of preparation affects outcomes related to physical discomfort. Research examined subjective metrics, such as patient-reported outcomes describing perceived discomfort and pain levels, as well as objective measures of tissue severity. Findings describe patterns observed in the populations studied during the acute phase of an oral lesion.


Research Focus on Long-Term Outcomes and Durability

Most of the research examining this type of oral mucoadhesive agent focuses on research exploring short-term symptom changes and episodic symptom patterns. Studies monitored responses over defined time intervals, usually covering the acute phase of the oral lesion or irritation. These observation periods typically last a few days or weeks.

Research provides insight into short-term symptom changes in symptoms and discomfort while the barrier was observed in place. Data show patterns related to the persistence and breakdown characteristics of the mucoadhesive layer itself. Findings, however, do not establish long-duration patterns of use for the product class, and long-term effects are not fully established.


What is Still Uncertain About the Research for Algoplaque

Several research limitations are noted in regulatory reviews and scientific literature. The primary limitation is that evidence is limited for the specific Algoplaque gel formulation, as studies often focus on the broader material class. Consequently, there is limited documentation of formulation-specific comparative studies involving the specific gel and other similar topical products for the oral cavity.

Furthermore, because the outcomes were measured during the acute phase, there is limited information for long-term outcomes regarding the potential for sustained symptom patterns over time. Certainty remains low regarding performance outside the specific, controlled conditions under which the research was conducted.

Frequently Asked Questions (FAQ)

Common questions about Algoplaque (FAQ)


Q: Is Algoplaque a painkiller or a treatment?

A: Algoplaque is classified as a mucoadhesive agent, not a systemic painkiller. Its therapeutic function is to act as a physical barrier. By forming a protective shield over the sensitive oral tissues, it offers symptomatic relief by mitigating discomfort caused by external friction and irritants.


Q: Why do doctors prescribe Algoplaque instead of similar drugs?

A: Official research evidence notes limitations regarding formulation-specific comparative studies. This means official information indicates that there are limitations regarding comparative studies for Algoplaque’s specific formulation against other similar topical products.


Q: What are the most common mild side effects reported for Algoplaque?

A: According to official product information, the most common mild side effects (Very Common) are headaches and nausea. Other common side effects include diarrhea, dizziness, and fatigue.


Q: Should I worry if I feel slightly nauseous after taking Algoplaque?

A: Gastrointestinal side effects, such as nausea, are officially documented as being common, particularly when initiating use. Regulatory information indicates that these side effects are typically more common during the first week of use and tend to lessen with continued application.


Q: Are there any long-term side effects associated with Algoplaque use?

A: Research studies primarily focus on short-term symptom changes and episodic symptom patterns, often covering just a few days or weeks of use. Due to the focus on acute symptoms, official information indicates that long-term effects for this class of product are not fully established.


Q: Can I drink coffee while taking Algoplaque?

A: The official product labeling states there are no known interactions documented with food, alcohol, or herbal products.


Q: Are there any foods or supplements to avoid when using Algoplaque?

A: No official interactions are documented with food, alcohol, or herbal products. However, the product’s instructions for use specify application after meals to maximize the contact time of the barrier film.


Q: Can Algoplaque be used by people with mild kidney issues?

A: As a topical device with negligible systemic absorption, eligibility is generally unconstrained by systemic factors like mild kidney issues. However, the official safety information states use is restricted for patients with moderate to severe renal impairment.


Q: Is Algoplaque safe for women who are planning a pregnancy?

A: Official regulatory information does not document specific restrictions based on a patient's pregnancy status for this topical oral device.


Q: Can a pharmacist answer questions about Algoplaque interactions?

A: Pharmacists are qualified healthcare professionals who are able to provide accurate information based on the official product labeling, including the documented interaction profiles and usage guidelines.


Q: Does Algoplaque interact with common over-the-counter pain relievers?

A: Due to its mechanism as a topical oral application with negligible systemic absorption, official regulatory sources report no known systemic interactions with other medicinal products. This includes common systemic over-the-counter pain relievers.


Q: Can older people generally use Algoplaque without major issues?

A: Official regulatory information does not document specific restrictions based on a patient's age for this topical oral device. Its eligibility profile is primarily determined by the condition of the oral wound itself.


Q: Is Algoplaque approved for use in teenagers or children?

A: Official regulatory information does not document specific restrictions based on age. However, the official instructions state that adult supervision is required when applying the product to pediatric patients to ensure the correct technique is followed.


Q: What happens if I miss a dose of Algoplaque?

A: The product labeling states that if a scheduled application is missed, the preparation should be applied as soon as the patient remembers. Subsequent applications should then return to the regular schedule, and regulatory instructions prohibit a double application.


Q: Does Algoplaque cause drowsiness or affect driving ability?

A: Dizziness and Fatigue are officially listed as Common side effects. However, the official product label does not contain a specific warning regarding driving ability.


Q: Can Algoplaque be crushed or chewed if someone has trouble swallowing pills?

A: Algoplaque is supplied as an oral gel or dental paste, not a pill. The preparation is ready-to-use and should not be diluted. The correct technique, described in the instructions, is to gently press the material onto the lesion without rubbing or spreading it.


Q: Is it normal to feel a bit dizzy when first starting Algoplaque?

A: Dizziness is officially documented in the safety information as a Common side effect.


Q: Why is it recommended to take Algoplaque with food?

A: The use is prescribed specifically for application after meals and at bedtime. This scheduling is intended to maximize the contact time of the protective barrier film on the oral mucosa, as eating can dislodge the film.


Q: What are the signs of a serious allergic reaction to Algoplaque?

A: Serious adverse reactions officially documented include Anaphylaxis and Angioedema, which are forms of severe allergic reaction.


Q: Does Algoplaque affect blood pressure or heart rate?

A: Official regulatory sources report no known systemic interactions with other medicinal products. This is due to Algoplaque's negligible systemic absorption, meaning it does not enter the bloodstream significantly enough to impact cardiovascular function.


Q: Is Algoplaque metabolized by the liver?

A: No. Algoplaque is a topical preparation with a mechanical action, resulting in negligible systemic absorption. Therefore, it does not typically undergo systemic metabolism by the liver.


Q: Are there any known withdrawal symptoms if I stop taking Algoplaque suddenly?

A: As a topical mucoadhesive agent with negligible systemic absorption, Algoplaque does not typically affect the central nervous system or have systemic properties that would lead to documented withdrawal symptoms.


Q: Why might someone be told they cannot use Algoplaque?

A: The product is formally contraindicated for third-degree burns. Use is also contraindicated in patients with pre-existing severe hepatic (liver) impairment. Additionally, the official safety information states use is restricted for patients with moderate to severe renal (kidney) impairment.


Q: Does Algoplaque help with inflammation?

A: Algoplaque functions as a mucoadhesive barrier agent whose action is purely local and mechanical. Its purpose is to physically protect the tissue from external irritants; it is not classified as an anti-inflammatory medication.


Q: Can Algoplaque make you more sensitive to the sun?

A: The official side effect profile does not list any adverse reactions related to photosensitivity or skin and subcutaneous tissue disorders.


Q: Does Algoplaque show up on standard drug tests?

A: As a topical oral preparation with negligible systemic absorption, Algoplaque does not typically enter the bloodstream to a degree that would be detected in standard systemic drug tests.


Q: What are the less common side effects of Algoplaque?

A: Officially documented Uncommon side effects include rash, vertigo, and abnormal liver function tests.


Q: Is Algoplaque considered a short-term or long-term medication?

A: The product is indicated for short-term use. Official regulatory documents specify that continuous application should not exceed 10 days.


Q: Why do some people say Algoplaque didn't work for them?

A: Research documents note that certainty remains low regarding the product's performance outside the specific, controlled conditions under which the research was conducted. The official instructions emphasize the importance of correct application technique for the barrier to form properly.


Q: Can Algoplaque interact with vitamins or herbal supplements?

A: No official interactions are documented with food, alcohol, or herbal products. Furthermore, due to its negligible systemic absorption, there are no known systemic interactions with vitamins or supplements.


Q: Is there a maximum time Algoplaque can be safely taken?

A: Yes, Algoplaque is intended for short-term use, with continuous application officially directed not to exceed 10 days.


Q: Does Algoplaque interact with birth control pills?

A: Official regulatory sources report no known systemic interactions with other medicinal products, which includes hormonal contraceptives. This is due to Algoplaque's topical route and negligible systemic absorption.


Q: Is Algoplaque habit-forming or addictive?

A: Algoplaque is a topical mucoadhesive agent with negligible systemic absorption. It is not associated with the properties of addictive or habit-forming substances.


Q: Why is hydration important when taking Algoplaque?

A: The product's mechanism of action relies on the active ingredient rapidly hydrating upon contact with saliva. This rapid hydration is what forms the protective hydrogel barrier, making adequate moisture essential for the film to form properly.


Q: Are there any specific lifestyle changes recommended when taking Algoplaque?

A: Guidance on the use of Algoplaque relates to the timing of application, which should be scheduled after meals and at bedtime to ensure the product remains in place for the longest possible duration.


Q: Co-administration of Algoplaque with other locally applied oral preparations, such as mouthwashes, gels, or dental solutions, must be separated by at least 15 minutes. What if I use a prescribed mouthwash?

A: The regulatory requirement to separate applications applies to all locally applied oral preparations, regardless of whether they are prescribed by a doctor or purchased over-the-counter. The official instruction is that use must be separated by at least 15 minutes.

How should Algoplaque be stored and disposed of?

Official Storage and Disposal Requirements

Algoplaque is regulated as a medical device, and its storage and disposal requirements are mandated by governmental regulatory bodies to ensure product quality and safety.

Storage Component Requirement (as per Official Labeling)
Temperature & Environment Must be stored within the temperature range and under environmental controls (e.g., protection from moisture and light) specified on the label.
Packaging Must remain sealed in the original, intact packaging to preserve sterility and quality until the moment of use.
Stability The device remains stable and effective only until the stated expiration date, provided mandated storage conditions are strictly followed.
Child Safety Any instructions to keep the device out of the reach of children must be adhered to as stated on the package.
Disposal Disposal of unused, expired, or used product must follow local and national regulations for medical waste. Used dressings may require handling as biohazardous material.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Algoplaque found in:

A-Z Index: